The amplifier effect: How Pin1 empowers mutant p53

Breast Cancer Research

Volumn 13, Issue 5, 2011, Pages

  Hu, Hai ^a   Wulf, Gerburg M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN P53; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; ESTROGEN RECEPTOR; MUTANT PROTEIN; PEPTIDYL PROLYL CIS TRANS ISOMERASE NIMA INTERACTING 1;

AMPLIFIER; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; CELL CYCLE ARREST; DNA BINDING; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; NONHUMAN; NOTE; ONCOGENE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; ANIMAL; ARTICLE; BREAST TUMOR; CELL TRANSFORMATION; FAMILIAL CANCER; FEMALE; GENETICS; METABOLISM; MOUSE; MUTATION; BREAST CARCINOGENESIS; CANCER GRADING; GENE FUNCTION; GENOME ANALYSIS; ISOMERIZATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; LI-FRAUMENI SYNDROME; MICE; MUTATION; PEPTIDYLPROLYL ISOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054106796     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2941     Document Type: Note

References (16)

1. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990, 249:912-915. 10.1126/science.2144057, 2144057.
2. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med 1969, 71:747-752.
3. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen- Dale AL. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006, 12:1157-1167. 10.1158/1078-0432.CCR-05-1029, 16489069.
4. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010, 2:a001107. 10.1101/cshperspect.a001107, 2828285, 20182618.
5. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, Schneider C, Del Sal G. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011, 20:79-91. 10.1016/j.ccr.2011.06.004, 21741598.
6. Lee TH, Pastorino L, Lu KP. Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med 2011, 13:e21.
7. Lu PJ, Zhou XZ, Shen M, Lu KP. Function of WW domains as phosphoserineor phosphothreonine-binding modules. Science 1999, 283:1325-1328. 10.1126/science.283.5406.1325, 10037602.
8. Wulf G, Finn G, Suizu F, Lu KP. Phosphorylation-specific prolyl isomerization: is there an underlying theme?. Nat Cell Biol 2005, 7:435-441. 10.1038/ncb0505-435, 15867923.
9. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, Lu KP. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001, 20:3459-3472. 10.1093/emboj/20.13.3459, 125530, 11432833.
10. Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem 2002, 277:47976-47979. 10.1074/jbc.C200538200, 12388558.
11. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C, Del Sal G. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 2002, 419:853-857. 10.1038/nature01120, 12397362.
12. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L, Tang X, Lu KP, Xiao ZX. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002, 419:849-853. 10.1038/nature01116, 12397361.
13. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872. 10.1016/j.cell.2004.11.006, 15607981.
14. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 2001, 3:793-801. 10.1038/ncb0901-793, 11533658.
15. Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer 2008, 7:91. 10.1186/1476-4598-7-91, 2632646, 19077306.
16. Finn G, Lu KP. Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer. Curr Cancer Drug Targets 2008, 8:223-229. 10.2174/156800908784293622, 18473735.